{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:20:56Z","timestamp":1784647256959,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11596-023-2746-1","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T17:01:36Z","timestamp":1687021296000},"page":"733-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1007","volume":"43","author":[{"given":"Xu","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-lan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-feng","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"issue":"1","key":"2746_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ajh.24575","volume":"92","author":"A Rosko","year":"2017","unstructured":"Rosko A, Wang HL, de Lima M, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol, 2017,92(1):42\u201349","journal-title":"Am J Hematol"},{"issue":"3","key":"2746_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41409-021-01508-2","volume":"57","author":"A Shimoni","year":"2022","unstructured":"Shimoni A. Relapse of acute leukemia after a second allogeneic stem-cell transplantation; Is there any hope for cure? Bone Marrow Transplant, 2022,57(3):336\u2013337","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2746_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","volume":"15","author":"RHJ Collins","year":"1997","unstructured":"Collins RHJ, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol, 1997,15(2):433\u2013444","journal-title":"J Clin Oncol"},{"issue":"10","key":"2746_CR4","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 2012,120(10):2032\u20132041","journal-title":"Blood"},{"issue":"3","key":"2746_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bbmt.2013.11.020","volume":"20","author":"AM Zeidan","year":"2014","unstructured":"Zeidan AM, Forde PM, Symons H, et al. HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant, 2014,20(3):314\u2013318","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2746_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/bmt.2014.217","volume":"50","author":"A Ghiso","year":"2015","unstructured":"Ghiso A, Raiola AM, Gualandi F, et al. DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant, 2015,50(1):56\u201361","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2746_CR7","first-page":"802","volume":"14","author":"ML Davila","year":"2016","unstructured":"Davila ML, Brentjens RJ. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol, 2016,14(10):802\u2013808","journal-title":"Clin Adv Hematol Oncol"},{"issue":"9","key":"2746_CR8","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei P, Singh H, Huls MH, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest, 2016,126(9):3363\u20133376","journal-title":"J Clin Invest"},{"issue":"26","key":"2746_CR9","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood, 2016,127(26):3321\u20133330","journal-title":"Blood"},{"issue":"26","key":"2746_CR10","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","volume":"127","author":"JH Park","year":"2016","unstructured":"Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood, 2016,127(26):3312\u20133320","journal-title":"Blood"},{"issue":"16","key":"2746_CR11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 2014,371(16):1507\u20131517","journal-title":"N Engl J Med"},{"issue":"320","key":"2746_CR12","doi-asserted-by":"publisher","first-page":"320ra323","DOI":"10.1126\/scitranslmed.aad5222","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh N, Perazzelli J, Grupp SA, et al. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med, 2016,8(320):320ra323","journal-title":"Sci Transl Med"},{"issue":"6","key":"2746_CR13","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang XQ, Zhang RL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia, 2021,35(6):1563\u20131570","journal-title":"Leukemia"},{"issue":"6","key":"2746_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/CJI.0000000000000233","volume":"41","author":"C Zhang","year":"2018","unstructured":"Zhang C, Kong PY, Li S, et al. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed\/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. J Immunother, 2018,41(6):306\u2013311","journal-title":"J Immunother"},{"issue":"4","key":"2746_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant, 2019,25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2746_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant, 2015,21(3):389\u2013401","journal-title":"Biol Blood Marrow Transplant"},{"key":"2746_CR17","unstructured":"Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021). Zhonghua Xue Ye Xue Za Zhi (Chinese), 2021,42(4):265\u2013275"},{"issue":"4","key":"2746_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14712598.2011.554811","volume":"11","author":"C Roddie","year":"2011","unstructured":"Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther, 2011,11(4):473\u2013487","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"2746_CR19","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","volume":"112","author":"HJ Kolb","year":"2008","unstructured":"Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood, 2008,112(12):4371\u20134383","journal-title":"Blood"},{"issue":"5","key":"2746_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","volume":"26","author":"RH Collins Jr.","year":"2000","unstructured":"Collins RH, Jr., Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant, 2000,26(5):511\u2013516","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2746_CR21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/ajh.25274","volume":"93","author":"E Jacoby","year":"2018","unstructured":"Jacoby E, Bielorai B, Avigdor A, et al. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol, 2018,93(12):1485\u20131492","journal-title":"Am J Hematol"},{"issue":"5","key":"2746_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med, 2018,378(5):449\u2013459","journal-title":"N Engl J Med"},{"issue":"4","key":"2746_CR23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/bjh.14923","volume":"179","author":"Y Chen","year":"2017","unstructured":"Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol, 2017,179(4):598\u2013605","journal-title":"Br J Haematol"},{"issue":"5","key":"2746_CR24","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41409-020-01140-6","volume":"56","author":"J Hua","year":"2021","unstructured":"Hua J, Zhang J, Zhang X, et al. Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 2021,56(5):1056\u20131064","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2746_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nm.4258","volume":"23","author":"A Ghosh","year":"2017","unstructured":"Ghosh A, Smith M, James SE, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med, 2017,23(2):242\u2013249","journal-title":"Nat Med"},{"issue":"2","key":"2746_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/imt-2016-0127","volume":"9","author":"F Anwer","year":"2017","unstructured":"Anwer F, Shaukat AA, Zahid U, et al. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy, 2017,9(2):123\u2013130","journal-title":"Immunotherapy"},{"issue":"5","key":"2746_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med, 2018,378(5):439\u2013448","journal-title":"N Engl J Med"},{"key":"2746_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev, 2019,34:45\u201355","journal-title":"Blood Rev"},{"issue":"3","key":"2746_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","volume":"183","author":"KA Hay","year":"2018","unstructured":"Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol, 2018,183(3):364\u2013374","journal-title":"Br J Haematol"},{"issue":"9","key":"2746_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.clml.2016.06.005","volume":"16","author":"MM Al Malki","year":"2016","unstructured":"Al Malki MM, Aldoss I, Stiller T, et al. Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma and Leuk, 2016,16(9):519\u2013522","journal-title":"Clin Lymphoma Myeloma and Leuk"},{"issue":"5","key":"2746_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00277-017-2941-x","volume":"96","author":"SP Haen","year":"2017","unstructured":"Haen SP, Groh C, Schumm M, et al. Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. Ann Hematol, 2017,96(5):817\u2013827","journal-title":"Ann Hematol"},{"issue":"5","key":"2746_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjh.15973","volume":"186","author":"A Nagler","year":"2019","unstructured":"Nagler A, Labopin M, Dholaria B, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol, 2019,186(5):767\u2013776","journal-title":"Br J Haematol"},{"issue":"12","key":"2746_CR33","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/bmt.2015.186","volume":"50","author":"T Ruutu","year":"2015","unstructured":"Ruutu T, de Wreede LC, van Biezen A, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant, 2015,50(12):1542\u20131550","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2746_CR34","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00277-018-3454-y","volume":"97","author":"C Schneidawind","year":"2018","unstructured":"Schneidawind C, Hagmaier V, Faul C, et al. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. Ann Hematol, 2018,97(12):2491\u20132500","journal-title":"Ann Hematol"},{"issue":"26","key":"2746_CR35","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","volume":"31","author":"M Christopeit","year":"2013","unstructured":"Christopeit M, Kuss O, Finke J, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol, 2013,31(26):3259\u20133271","journal-title":"J Clin Oncol"},{"issue":"15","key":"2746_CR36","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol, 2021,39(15):1650\u20131659","journal-title":"J Clin Oncol"},{"issue":"5","key":"2746_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Shaw PA, Hexner EO, et al. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2020,38(5):415\u2013422","journal-title":"J Clin Oncol"},{"issue":"10","key":"2746_CR38","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ajh.25582","volume":"94","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li C, Yin P, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am J Hematol, 2019,94(10):1113\u20131122","journal-title":"Am J Hematol"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2746-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-023-2746-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2746-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:12:58Z","timestamp":1692681178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-023-2746-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2746"],"URL":"https:\/\/doi.org\/10.1007\/s11596-023-2746-1","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}